Vivus posts shortfall in Qsymia sales; Boehringer, Lilly unveil diabetes education push for doctors;

@FiercePharma: India's own drugmakers are turned off their home market by gov't policy. For them, it's price caps. More | Follow @FiercePharma

@EricPFierce: Rapidly growing Sagent takes control of FDA approved China plant that is ready to produce products. Article | Follow @EricPFierce

> Vivus ($VVUS) reported weaker-than-expected sales of its weight-loss pill Qsymia for the first quarter, with product revenue at $4.1 million. Report

> Only half of people infected with hepatitis C in the U.S. actually get proper testing to determine whether they need treatment, public health officials say. Report

> Boehringer Ingelheim and Eli Lilly ($LLY) have developed a joint education campaign for doctors to better illuminate the mechanisms behind one of their Type 2 diabetes drugs. Report

> Bristol-Myers Squibb's ($BMY) HIV fighter Sustiva won a new indication from FDA for use in pediatric patients from three months to three years of age. Report

> Private-label over-the-counter drugmaker Perrigo reported record quarterly revenue with $920 million in net sales, up 18% year over year. Report

> Generics maker Akorn posted a 43% increase in revenue to $73.8 million for the first quarter, falling short of analysts' estimates of $74.1 million; the company also lowered its forecast on a slower-than-expected Superstorm Sandy recovery. Report

Medical Device News

@FierceMedDev: FDA warns of criminals hocking stolen Covidien stapler reloads. More | Follow @FierceMedDev

@MarkHFierce: Biotronik won FDA approval for ICD/CRT-D devices, keeping it in the global race to unveil new products in the space. Story | Follow @MarkHFierce

 @DamianFierce: Stan Musial rises from the grave and takes a job at a specialty pharma outfit. Amazing, really. Release | Follow @DamianFierce

> ArthroCare's Q1 numbers come in flat. Article

> Good Start Genetics raises $28M for carrier Dx. News

Biotech News

@FierceBiotech: Nimbus Discovery announced agreement with Shire focused on small molecule treatments for rare genetic diseases. Release | Follow @FierceBiotech

@JohnCFierce: Painful to watch Vivus ($VVUS) scratching out sales for its weight drug. It's not built to market a drug like that. More | Follow @JohnCFierce

@RyanMFierce: Pfizer opts to keep running Accelrys software in its labs. Article | Follow @RyanMFierce

> Genomics, Biotechnology's Oldest Next Big Thing. Industry Voices

> Startup biotech charges into PhII with $23M bankroll for rare disease drugs. Article

> Takeda beefs up new vaccines arm with $250M bolt-on buyout of Inviragen. News

Drug Delivery News

@MichaelGFierce: Frederick National Lab leads nanotech boom with cancer drug delivery. Report | Follow @MichaelGFierce

> 'Buckyball' capsule lets researchers steer drugs to target. Article

> Math model could choose most effective drug delivery nanoparticle. Story

> Langer's Kala touts positive results for topical wet AMD treatment. Report

> 'Smart' insulin nanoparticle controls blood sugar levels for up to 10 days. More

And Finally... A quick uptick in deaths and infections from a SARS-like virus in Saudi Arabia has officials worried. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.